SAN

81.63

+0.28%↑

UCB

258.3

-0.73%↓

SHL.DE

38.26

-0.21%↓

ARGX

710.4

+0.4%↑

VIE

35.02

-1.21%↓

SAN

81.63

+0.28%↑

UCB

258.3

-0.73%↓

SHL.DE

38.26

-0.21%↓

ARGX

710.4

+0.4%↑

VIE

35.02

-1.21%↓

SAN

81.63

+0.28%↑

UCB

258.3

-0.73%↓

SHL.DE

38.26

-0.21%↓

ARGX

710.4

+0.4%↑

VIE

35.02

-1.21%↓

SAN

81.63

+0.28%↑

UCB

258.3

-0.73%↓

SHL.DE

38.26

-0.21%↓

ARGX

710.4

+0.4%↑

VIE

35.02

-1.21%↓

SAN

81.63

+0.28%↑

UCB

258.3

-0.73%↓

SHL.DE

38.26

-0.21%↓

ARGX

710.4

+0.4%↑

VIE

35.02

-1.21%↓

Strona główna・Stock List・Laboratorios Farmaceuticos Rovi SA

Laboratorios Farmaceuticos Rovi SA

Open

SectorHealthcare

84.4 0.18

Buy Sell

Overview

Share price change

24h

Current

Min

83.45

Max

84.65

Key metrics
By Trading Economics
Income	-33M 43M
Sales	7.9M 218M
P/E Sector Avg	35.869 63.808
EPS	0.834
Profit margin	19.539
Employees	1,950
EBITDA	-21M 63M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+2.54% upside

Dividends
By Dow Jones
Next Earnings	6 maj 2026

Market Stats
By TradingEconomics
Market Cap	353M 4.3B
Previous open	84.22
Previous close	84.4

News Sentiment

By Acuity

50%

162 / 348 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Weak Bullish Evidence

51.1 / N/A Support & Resistance

Laboratorios Farmaceuticos Rovi SA Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

16 kwi 2026, 23:26 UTC

Hot Stocks

Stocks to Watch: Netflix, Alcoa, Knight-Swift, NiSource

16 kwi 2026, 20:41 UTC

Major Market Movers

Netflix Shares Slide After 2Q Outlook Misses Wall Street's Expectations

16 kwi 2026, 23:49 UTC

Market Talk

Amplitude's Pivot to Oil-Linked Supply Deal Catches Bull's Eye -- Market Talk

16 kwi 2026, 23:45 UTC

Market Talk

Nikkei May Decline After Hitting Record High -- Market Talk

16 kwi 2026, 23:33 UTC

Market Talk

Major News Events

Gold Edges Higher on Hopes for U.S.-Iran Deal -- Market Talk

16 kwi 2026, 22:51 UTC

Market Talk

Netflix Sees Signs That Podcasts May Boost Engagement -- Market Talk

16 kwi 2026, 22:08 UTC

Earnings

Netflix Chair Reed Hastings to Leave Board in June -- 3rd Update

16 kwi 2026, 22:06 UTC

Earnings

Lundin Mining: Earnings From Discontinued Ops in 1Q Expected to Be Positively Impacted by Unaudited Gain on Disposal of Eagle Mine, Totaling Approximately $4M >LUN.T

16 kwi 2026, 22:06 UTC

Earnings

Lundin Mining: Pre-Announces Items Impacting 1Q Results

16 kwi 2026, 22:06 UTC

Earnings

Lundin Mining: Items of Significant Impact in 1Q Expected to Include Unaudited Realized Losses on Derivative Contracts of Approximately $13M, Primarily Related to Gold Collar Contracts >LUN.T

16 kwi 2026, 22:06 UTC

Earnings

Lundin Mining: Rev in 1Q Expected to Be Positively Impacted by Unaudited Provisional Pricing Adjustments on Prior-Period Concentrate Sales of Approximately $22M on Pre-Tax Basis >LUN.T

16 kwi 2026, 22:06 UTC

Earnings

Lundin Mining: Adjustments Primarily Include Upward Adjustments in Relation to Prior-Period Metal Sales >LUN.T

16 kwi 2026, 20:50 UTC

Market Talk

Earnings

Tech, Media & Telecom Roundup: Market Talk

16 kwi 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

16 kwi 2026, 20:50 UTC

Market Talk

Major News Events

Basic Materials Roundup: Market Talk

16 kwi 2026, 20:50 UTC

Market Talk

Earnings

Health Care Roundup: Market Talk

16 kwi 2026, 20:49 UTC

Earnings

SpaceX Is Ready to Go Public. The Stock Market Is Its Rocket. -- Barrons.com

16 kwi 2026, 20:43 UTC

Earnings

Update: Netflix Stock Falls on Weak Guidance. Founder Reed Hastings Is Leaving the Board. -- Barrons.com

16 kwi 2026, 20:40 UTC

Market Talk

Earnings

Global Equities Roundup: Market Talk

16 kwi 2026, 20:40 UTC

Market Talk

Earnings

Netflix Says Engagement Quality Hits New High -- Market Talk

16 kwi 2026, 20:30 UTC

Hot Stocks

Stocks to Watch: TSMC, Abbott Laboratories, Nvidia, Netflix -- WSJ

16 kwi 2026, 20:25 UTC

Earnings

Netflix Stock Falls on Weak Guidance. Founder Reed Hastings Is Leaving the Board. -- Barrons.com

16 kwi 2026, 20:23 UTC

Earnings

These Stocks Are Today's Movers: AMD, Intel, TSMC, Abbott, Hims, Corning, Schwab, Polaris, and More -- Barrons.com

16 kwi 2026, 20:19 UTC

Earnings

Netflix Guidance Disappoints. The Stock Is Down. -- Barrons.com

16 kwi 2026, 20:17 UTC

Earnings

Alcoa: Alumina Costs in the Aluminum Segment Are Expected to Be Favorable by Approximately $20M Sequentially >AA

16 kwi 2026, 20:17 UTC

Earnings

Alcoa: Based on Higher LME and Midwest Premium Pricing and Expected Higher Shipments, Section 232 Tariff Costs on U.S. Imports of Aluminum From Canada Expected to Increase $35M Sequentially >AA

16 kwi 2026, 20:16 UTC

Earnings

Alcoa: Expects 2026 Total Aluminum Segment Production and Shipments Ranging Between 2.4M and 2.6M Metric Tons, and Between 2.6M and 2.8M Metric Tons, Respectively >AA

16 kwi 2026, 20:16 UTC

Earnings

Alcoa: Expects 2026 Total Aluminum Segment Production and Shipments to Remain Unchanged From Its Prior Projection >AA

16 kwi 2026, 20:16 UTC

Earnings

Alcoa: Expects 2026 Total Alumina Segment Production and Shipments Ranging Between 9.7M to 9.9M Metric Tons, and Between 11.8M and 12.0M Metric Tons, Respectively >AA

16 kwi 2026, 20:16 UTC

Earnings

Alcoa: Expects 2026 Total Alumina Segment Production and Shipments to Remain Unchanged From Prior Projection >AA

Peer Comparison

Price change

Laboratorios Farmaceuticos Rovi SA Forecast

Price Target

By TipRanks

2.54% upside

12 Months Forecast

Average 86.75 EUR 2.54%

High 90 EUR

Low 83.5 EUR

Based on 2 Wall Street analysts offering 12 month price targets forLaboratorios Farmaceuticos Rovi SA - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

2 ratings

Buy

Hold

Sell

Based on 2 analysts giving stock ratings to Laboratorios Farmaceuticos Rovi SA - Dist in the past 3 months.

Technical Score

By Trading Central

51.1 / N/ASupport & Resistance

Recent bullish events outweigh bearish events.

Bearish events outweigh bullish events.

Sentiment

By Acuity

162 / 348 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Laboratorios Farmaceuticos Rovi SA

Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally. The company provides products for cardiology, osteoarticular/women's health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. Its principal products include Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa; and hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Express, Fibrilin, and Sodium Heparin Rovi. It also provides contract-manufacturing services to other companies for a range of pharmaceutical forms, including prefilled syringes, vials, suppositories, tablets, and sachets. Laboratorios Farmaceuticos Rovi, S.A. was incorporated in 1946 and is headquartered in Madrid, Spain. Laboratorios Farmaceúticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L.